Alfredo Pauciulo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alfredo Pauciulo has a total of 188 co-authors. Here are the top co-authors by number of shared publications:
- Emilio Lozupone
Department of Neuroradiology, Vito Fazzi Hospital, Lecce, Italy
5 shared publications - Adriana Paladini
Department of Neuroradiology, Vito Fazzi Hospital, Lecce, Italy
3 shared publications - Alessio Vitiello
Department of Neuroradiology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
2 shared publications - Antonio Fasano
Department of Neurology, Hospital Vito Fazzi, Lecce, Italy
2 shared publications - Daniele Giuseppe Romano
Department of Diagnostic and Interventional Neuroradiology, Ospedali Riuniti San Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy
2 shared publications - Domenico Sergio Zimatore
Neuroradiologia, Azienda Ospedaliera Consordiale Policlinico di Bari, Bari, Italy
2 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by Springer Nature in Neuroradiology
- p. 1-12
Antithrombogenic coated self-expanding stent (pEGASUS-HPC) for the treatment of intracranial dissections of the cerebral arteries in acute stroke: a multicenter study
Background: Intracranial artery dissection (IADS) is an uncommon cause of acute ischemic stroke (AIS). In hyperacute settings, stenting is constrained by the need for intensive antiplatelet therapy. This study evaluated the antithrombogenic hydrophilic polymer–coated pEGASUS-HPC self-expanding stent for IADS-related AIS. Methods: This multicenter retrospective cohort study across seven stroke centers included consecutive patients with AIS and occlusion or severe flow-limiting stenosis caused by symptomatic IADS, who were treated with the pEGASUS-HPC. The outcomes were technical and angiographic success (device opening; mTICI score ≥2b when reperfusion was targeted), peri-procedural complications, mRS score, and follow-up patency. Results: In 36 treated patients (mean age 62.0 ± 19.6 years; 63.9% men), 91.7% of the dissections were spontaneous, and 80.6% were occlusive. Mechanical thrombectomy preceded stenting in 26/29 occlusive cases. Full stent opening occurred in 94.4%, and 100% reperfusion success was achieved in targeted vessels. Most patients received periprocedural intravenous antiplatelet bridging (75.0%) and were discharged on DAPT (77.8%). Whereas no intraprocedural complications occurred, four postprocedural events occurred during admission (11.1%), of which two were clinically significant and two were minor and asymptomatic. The mean NIHSS score improved from 11.8 at admission to 4.9 at discharge, and the mean discharge mRS score was 2.1. Clinical follow-up (mRS) was available in 33/36 patients (91.7%), with favorable functional outcome (mRS 0–2) in 27/33 (81.8%). Imaging follow-up at the early window (mean 94 days) was available in 27/36 (75.0%). In-stent stenosis ≥ 50% occurred in 14.8% and 4.2% of patients at early and mid-term follow-up, respectively, whereas no device occlusions or recurrent strokes occurred through mid-term follow-up. Long-term imaging follow-up (15/36, 41.7%) showed no new in-stent stenosis. Conclusions: pEGASUS-HPC stenting for IADS-related AIS was technically feasible and achieved high reperfusion rates and a low overall complication burden, thus supporting prospective evaluation with standardized antiplatelet protocols.
- 30 July 2026
- Published by Springer Nature in Neuroradiology
- p. 1-12
Open AccessAntithrombogenic coated self-expanding stent (pEGASUS-HPC) for the treatment of intracranial dissections of the cerebral arteries in acute stroke: a multicenter study
Background: Intracranial artery dissection (IADS) is an uncommon cause of acute ischemic stroke (AIS). In hyperacute settings, stenting is constrained by the need for intensive antiplatelet therapy. This study evaluated the antithrombogenic hydrophilic polymer–coated pEGASUS-HPC self-expanding stent for IADS-related AIS. Methods: This multicenter retrospective cohort study across seven stroke centers included consecutive patients with AIS and occlusion or severe flow-limiting stenosis caused by symptomatic IADS, who were treated with the pEGASUS-HPC. The outcomes were technical and angiographic success (device opening; mTICI score ≥2b when reperfusion was targeted), peri-procedural complications, mRS score, and follow-up patency. Results: In 36 treated patients (mean age 62.0 ± 19.6 years; 63.9% men), 91.7% of the dissections were spontaneous, and 80.6% were occlusive. Mechanical thrombectomy preceded stenting in 26/29 occlusive cases. Full stent opening occurred in 94.4%, and 100% reperfusion success was achieved in targeted vessels. Most patients received periprocedural intravenous antiplatelet bridging (75.0%) and were discharged on DAPT (77.8%). Whereas no intraprocedural complications occurred, four postprocedural events occurred during admission (11.1%), of which two were clinically significant and two were minor and asymptomatic. The mean NIHSS score improved from 11.8 at admission to 4.9 at discharge, and the mean discharge mRS score was 2.1. Clinical follow-up (mRS) was available in 33/36 patients (91.7%), with favorable functional outcome (mRS 0–2) in 27/33 (81.8%). Imaging follow-up at the early window (mean 94 days) was available in 27/36 (75.0%). In-stent stenosis ≥ 50% occurred in 14.8% and 4.2% of patients at early and mid-term follow-up, respectively, whereas no device occlusions or recurrent strokes occurred through mid-term follow-up. Long-term imaging follow-up (15/36, 41.7%) showed no new in-stent stenosis. Conclusions: pEGASUS-HPC stenting for IADS-related AIS was technically feasible and achieved high reperfusion rates and a low overall complication burden, thus supporting prospective evaluation with standardized antiplatelet protocols.
- 8 June 2026
- Published by Wolters Kluwer Health in Neurosurgery
The Revolve Study: A Multicenter Registry Using the Flow Diverter Surpass Evolve® Device for the Endovascular Treatment of Intracranial Aneurysms
BACKGROUND AND OBJECTIVE: Flow diverter devices have revolutionized the treatment of intracranial aneurysms, but evidence on newer-generation devices remains limited. The Surpass Evolve (SE) was designed to improve deliverability and vessel wall apposition compared with its predecessors. This registry aimed to evaluate the feasibility, safety, and efficacy of SE in a large, real-world multicenter cohort with long-term follow-up. METHODS: Between May 2019 and December 2022, 275 consecutive aneurysms in 272 patients were treated with the SE flow diverter across 28 Italian centers. Clinical and imaging follow-up was completed by January 2024. Mid-term (≤6 months) and long-term (≤24 months) follow-ups, including clinical assessment, angiography, and cross-sectional imaging (computed tomography/magnetic resonance), were systematically collected and independently reviewed by a central Core Lab. RESULTS: The mean maximum diameter of the aneurysm was 11.2 mm, and the mean neck size was 5.4 mm. A total of 258 aneurysms were unruptured (93.8%), and 17 (6.2%) were ruptured. The majority arose from the anterior circulation (87.6%), with 12.4% in the posterior circulation. Device deployment was unsuccessful in 5/278 procedures (1.8%), and misdeployment occurred in 28/278 (10%). The overall device-related mortality was 0.7%, and the morbidity was 5.4%. At mid-term follow-up, complete or near-complete occlusion was achieved in 66% of aneurysms, increasing to 92% at long-term. According to mass criteria, 82% of aneurysms were considered cured, whereas sac enlargement occurred in 0.5% and 17% remained unchanged in volume. CONCLUSION: Our experience using SE for endovascular treatment of intracranial aneurysms showed a high safety and efficacy profile, substantially equivalent to that of the other flow diverter devices commonly used.
- 8 June 2026
- Published by Wolters Kluwer Health in Neurosurgery
The Revolve Study: A Multicenter Registry Using the Flow Diverter Surpass Evolve® Device for the Endovascular Treatment of Intracranial Aneurysms
BACKGROUND AND OBJECTIVE: Flow diverter devices have revolutionized the treatment of intracranial aneurysms, but evidence on newer-generation devices remains limited. The Surpass Evolve (SE) was designed to improve deliverability and vessel wall apposition compared with its predecessors. This registry aimed to evaluate the feasibility, safety, and efficacy of SE in a large, real-world multicenter cohort with long-term follow-up. METHODS: Between May 2019 and December 2022, 275 consecutive aneurysms in 272 patients were treated with the SE flow diverter across 28 Italian centers. Clinical and imaging follow-up was completed by January 2024. Mid-term (≤6 months) and long-term (≤24 months) follow-ups, including clinical assessment, angiography, and cross-sectional imaging (computed tomography/magnetic resonance), were systematically collected and independently reviewed by a central Core Lab. RESULTS: The mean maximum diameter of the aneurysm was 11.2 mm, and the mean neck size was 5.4 mm. A total of 258 aneurysms were unruptured (93.8%), and 17 (6.2%) were ruptured. The majority arose from the anterior circulation (87.6%), with 12.4% in the posterior circulation. Device deployment was unsuccessful in 5/278 procedures (1.8%), and misdeployment occurred in 28/278 (10%). The overall device-related mortality was 0.7%, and the morbidity was 5.4%. At mid-term follow-up, complete or near-complete occlusion was achieved in 66% of aneurysms, increasing to 92% at long-term. According to mass criteria, 82% of aneurysms were considered cured, whereas sac enlargement occurred in 0.5% and 17% remained unchanged in volume. CONCLUSION: Our experience using SE for endovascular treatment of intracranial aneurysms showed a high safety and efficacy profile, substantially equivalent to that of the other flow diverter devices commonly used.
- 18 December 2025
- Published by Springer Nature in Neuroradiology
- Vol. 68 (4) , 1047-1056
Real-world use of the pEGASUS-HPC stent in cerebral aneurysms: results from a multicenter retrospective series
Background and purpose Stent-assisted coiling has revolutionized the treatment of wide-neck intracranial aneurysms. Several technical improvements have since emerged, including enhanced deliverability, low-profile designs, and reduced surface thrombogenicity. This study aimed to assess the real-world feasibility, safety, and efficacy of the pEGASUS-HPC device for intracranial aneurysms. Materials and methods This independent, multicenter, retrospective observational study evaluated patients treated with pEGASUS-HPC stent-assisted coiling between April 2022 and December 2024. Data on procedural outcomes, complications (technical and clinical), and imaging follow-up were analyzed. Results Ninety-nine aneurysms (30 ruptured (30.3%), 69 unruptured (69.7%)) in 98 patients (58 female (59.2%), 40 male (40.8%) were treated using 130 pEGASUS-HPC stents. The successful deployment rate was 97%. Device-related mortality and morbidity were 2% and 1%, respectively. Ischemic complication rates did not significantly differ between acute and elective cases or between single and dual antiplatelet therapy groups. Adequate occlusion (Raymond-Roy Class I–II) was achieved in 95% immediately post-procedure and 93% at follow-up (median 240 days). Conclusions The pEGASUS-HPC stent shows high feasibility, safety, and effectiveness in the treatment of intracranial aneurysms. Further research is warranted to assess the impact of its surface coating, especially in emergency settings.
- 18 December 2025
- Published by Springer Nature in Neuroradiology
- Vol. 68 (4) , 1047-1056
Real-world use of the pEGASUS-HPC stent in cerebral aneurysms: results from a multicenter retrospective series
Background and purpose Stent-assisted coiling has revolutionized the treatment of wide-neck intracranial aneurysms. Several technical improvements have since emerged, including enhanced deliverability, low-profile designs, and reduced surface thrombogenicity. This study aimed to assess the real-world feasibility, safety, and efficacy of the pEGASUS-HPC device for intracranial aneurysms. Materials and methods This independent, multicenter, retrospective observational study evaluated patients treated with pEGASUS-HPC stent-assisted coiling between April 2022 and December 2024. Data on procedural outcomes, complications (technical and clinical), and imaging follow-up were analyzed. Results Ninety-nine aneurysms (30 ruptured (30.3%), 69 unruptured (69.7%)) in 98 patients (58 female (59.2%), 40 male (40.8%) were treated using 130 pEGASUS-HPC stents. The successful deployment rate was 97%. Device-related mortality and morbidity were 2% and 1%, respectively. Ischemic complication rates did not significantly differ between acute and elective cases or between single and dual antiplatelet therapy groups. Adequate occlusion (Raymond-Roy Class I–II) was achieved in 95% immediately post-procedure and 93% at follow-up (median 240 days). Conclusions The pEGASUS-HPC stent shows high feasibility, safety, and effectiveness in the treatment of intracranial aneurysms. Further research is warranted to assess the impact of its surface coating, especially in emergency settings.
- Open Access
- 21 July 2025
- Published by MDPI AG in Preprints.org
CT Perfusion Changes in Ischemic Stroke Due to Isolated Internal Carotid Artery Occlusions: From Severity Assessment to Therapy
Introduction: acute ischemic stroke (AIS) due to isolated extra-cranial internal carotid artery occlusion (i-ICAO) is clinically heterogenous, ranging from mild symptomatic cases to fatal hemispheric involvement. This depends on several factors, such as changes in intracranial hemodynamics and collateral pathways. There are no clear recommendations on the best treatment to adopt between endovascular therapy (EVT) and best medical treatment (BMT). We hypothesized that a patient-specific characterization of the extent of the affected brain parenchyma through the perfusion CT (PCT) may provide more accurate information on stroke severity and can help guide therapeutic management. Materials: from January 2020 to February 2025, we retrospectively examined 698 patients that were consecutively admitted for confirmed AIS and identified 25 patients with an AIS resulting from i-ICAO. Clinical, neuroimaging and procedural data were analyzed. Results: 17 out of 25 patients underwent EVT and 8/25 were treated with BMT. As compared with BMT group, patients undergoing EVT showed higher NIHSS score at hospital admission (14.1 ± 5.6 Vs 6.2 ± 4.8 respectively, p<0.05), wider mean penumbra volume (193.8 ± 147.1 ml Vs 30.0 ± 23.0 ml respectively, p<0.05) and a larger core volume (7.9 ± 8.6 ml Vs 0.9 ± 1.6 ml respectively, p<0.05). No difference in functional status at hospital discharge was showed between groups. ROC analysis showed that penumbra volume was a better predictor of EVT than NIHSS at hospital admission alone (AUC 0.94 and 0.85 respectively). Conclusions: in AIS due to i-ICAO, our findings showed that EVT was performed in subjects presenting with a more severe stroke; furthermore, the extent of the penumbral volume appears to better predict subjects referred for EVT. In conclusion, our data suggest that using PCT data to characterize the effects that i-ICAO exerts on intracranial hemodynamics could aid in the therapeutic strategy.
- 21 July 2025
- Published by MDPI AG in Preprints.org
Open AccessCT Perfusion Changes in Ischemic Stroke Due to Isolated Internal Carotid Artery Occlusions: From Severity Assessment to Therapy
Introduction: acute ischemic stroke (AIS) due to isolated extra-cranial internal carotid artery occlusion (i-ICAO) is clinically heterogenous, ranging from mild symptomatic cases to fatal hemispheric involvement. This depends on several factors, such as changes in intracranial hemodynamics and collateral pathways. There are no clear recommendations on the best treatment to adopt between endovascular therapy (EVT) and best medical treatment (BMT). We hypothesized that a patient-specific characterization of the extent of the affected brain parenchyma through the perfusion CT (PCT) may provide more accurate information on stroke severity and can help guide therapeutic management. Materials: from January 2020 to February 2025, we retrospectively examined 698 patients that were consecutively admitted for confirmed AIS and identified 25 patients with an AIS resulting from i-ICAO. Clinical, neuroimaging and procedural data were analyzed. Results: 17 out of 25 patients underwent EVT and 8/25 were treated with BMT. As compared with BMT group, patients undergoing EVT showed higher NIHSS score at hospital admission (14.1 ± 5.6 Vs 6.2 ± 4.8 respectively, p<0.05), wider mean penumbra volume (193.8 ± 147.1 ml Vs 30.0 ± 23.0 ml respectively, p<0.05) and a larger core volume (7.9 ± 8.6 ml Vs 0.9 ± 1.6 ml respectively, p<0.05). No difference in functional status at hospital discharge was showed between groups. ROC analysis showed that penumbra volume was a better predictor of EVT than NIHSS at hospital admission alone (AUC 0.94 and 0.85 respectively). Conclusions: in AIS due to i-ICAO, our findings showed that EVT was performed in subjects presenting with a more severe stroke; furthermore, the extent of the penumbral volume appears to better predict subjects referred for EVT. In conclusion, our data suggest that using PCT data to characterize the effects that i-ICAO exerts on intracranial hemodynamics could aid in the therapeutic strategy.
- Open Access
- 9 June 2025
- Published by SAGE Publications in Interventional Neuroradiology
The use of FD-HPC in Ruptured and Unruptured Aneurysms, the Italian Dataset (RUAID): Preliminary results on feasibility and safety
Background: The introduction of flow diverters (FDs) has revolutionized the treatment of complex intracranial aneurysms; subsequent surface modifications have extended their indications to ruptured, bifurcation, and distal aneurysms. The aim of this study is to assess the real-world feasibility and safety of HPC surface-modified devices in the treatment of ruptured and unruptured aneurysms. Methods: This independent, multicenter, prospective observational study evaluated the outcomes of patients treated with implanted Phenox p64 or p48 MW-HPC-FDs between 2020 and 2022. The sub-analysis of the procedures, complications (clinical and technical), and additional treatment requirements assessed the devices’ feasibility and safety in the peri-procedural period. Results: One hundred and forty aneurysms (35% ruptured and 65% unruptured) were treated in 140 patients (37 females and 103 males) using 153 HPC-FDs (111 p64 and 42 p48): 100 aneurysms were saccular (71%), 22 dissecting (16%), 13 fusiform (9%), and five blister-like (3.6%). The successful deployment rate was 97.9%. The overall peri-procedural mortality rate was 9%, including three device-related deaths (2.2%); the overall morbidity rate was 12.1% (6.4% severe, 3.6% mild, and 2.1% asymptomatic adverse events); 4.4% of the clinical adverse events were certainly device related, and 2.2% were probably device related. Conclusions: The use of p64 and p48 HPC-FDs is highly feasible and acceptably safe, although further data are needed to assess the impact of the coating on safety in emergency and elective procedures.
- 9 June 2025
- Published by SAGE Publications in Interventional Neuroradiology
Open AccessThe use of FD-HPC in Ruptured and Unruptured Aneurysms, the Italian Dataset (RUAID): Preliminary results on feasibility and safety
Background: The introduction of flow diverters (FDs) has revolutionized the treatment of complex intracranial aneurysms; subsequent surface modifications have extended their indications to ruptured, bifurcation, and distal aneurysms. The aim of this study is to assess the real-world feasibility and safety of HPC surface-modified devices in the treatment of ruptured and unruptured aneurysms. Methods: This independent, multicenter, prospective observational study evaluated the outcomes of patients treated with implanted Phenox p64 or p48 MW-HPC-FDs between 2020 and 2022. The sub-analysis of the procedures, complications (clinical and technical), and additional treatment requirements assessed the devices’ feasibility and safety in the peri-procedural period. Results: One hundred and forty aneurysms (35% ruptured and 65% unruptured) were treated in 140 patients (37 females and 103 males) using 153 HPC-FDs (111 p64 and 42 p48): 100 aneurysms were saccular (71%), 22 dissecting (16%), 13 fusiform (9%), and five blister-like (3.6%). The successful deployment rate was 97.9%. The overall peri-procedural mortality rate was 9%, including three device-related deaths (2.2%); the overall morbidity rate was 12.1% (6.4% severe, 3.6% mild, and 2.1% asymptomatic adverse events); 4.4% of the clinical adverse events were certainly device related, and 2.2% were probably device related. Conclusions: The use of p64 and p48 HPC-FDs is highly feasible and acceptably safe, although further data are needed to assess the impact of the coating on safety in emergency and elective procedures.
- Open Access
- 12 July 2024
- Published by MDPI AG in Brain Sciences
- Vol. 14 (7) , 697
Evaluation of Mild Cognitive Impairment through Perientorhinal/Hippocampal Imaging and Comprehensive Neuropsychological and Psychophysical Assessment
Mild cognitive impairment (MCI) is a significant concern as it is a risk factor for AD progression, and early detection is vital in order to delay dementia onset and enable potential therapeutic interventions. Olfactory impairment is recognized as a predictive biomarker in neurodegenerative processes. The aims of this study were to explore the degree of entorhinal cortical atrophy (ERICA) and the severity of MCI symptoms; to analyze magnetic resonance imaging (MRI) results for the entorhinal cortex, parahippocampal gyrus, peri entorhinal cortex, and the cerebellar tentorium; and to perform a comprehensive neuropsychological and psychophysical assessment. The main results highlighted that in our sample—multidomain amnesic MCI patients with hyposmic symptomatology—we found that ERICA scores were associated with the severity of anxiety symptomatology. One possible hypothesis to explain this observation is that anxiety may contribute to neurodegenerative processes by inducing chronic stress and inflammation. Future research should consider the longitudinal development of neuropsychological scores, anxiety disorders, and brain atrophy to determine their potential predictive value for MCI progression. These findings suggest the importance of psychological factors in MCI progression and the utility of neuropsychological assessment alongside neuroimaging techniques for early detection and follow-up in MCI patients.
- 12 July 2024
- Published by MDPI AG in Brain Sciences
- Vol. 14 (7) , 697
Open AccessEvaluation of Mild Cognitive Impairment through Perientorhinal/Hippocampal Imaging and Comprehensive Neuropsychological and Psychophysical Assessment
Mild cognitive impairment (MCI) is a significant concern as it is a risk factor for AD progression, and early detection is vital in order to delay dementia onset and enable potential therapeutic interventions. Olfactory impairment is recognized as a predictive biomarker in neurodegenerative processes. The aims of this study were to explore the degree of entorhinal cortical atrophy (ERICA) and the severity of MCI symptoms; to analyze magnetic resonance imaging (MRI) results for the entorhinal cortex, parahippocampal gyrus, peri entorhinal cortex, and the cerebellar tentorium; and to perform a comprehensive neuropsychological and psychophysical assessment. The main results highlighted that in our sample—multidomain amnesic MCI patients with hyposmic symptomatology—we found that ERICA scores were associated with the severity of anxiety symptomatology. One possible hypothesis to explain this observation is that anxiety may contribute to neurodegenerative processes by inducing chronic stress and inflammation. Future research should consider the longitudinal development of neuropsychological scores, anxiety disorders, and brain atrophy to determine their potential predictive value for MCI progression. These findings suggest the importance of psychological factors in MCI progression and the utility of neuropsychological assessment alongside neuroimaging techniques for early detection and follow-up in MCI patients.
- 17 July 2023
- Published by Springer Nature in Neurological Sciences
- Vol. 44 (12) , 4401-4410
IV thrombolysis plus thrombectomy versus IV thrombolysis alone for minor stroke with anterior circulation large vessel occlusion from the IRETAS and Italian SITS-ISTR cohorts
Introduction The aim of this study was to compare the outcomes of patients treated with intravenous thrombolysis (IVT) p=0.013) and higher rate of PH (OR, 4.363; 95% CI, 1.579–12.055; p=0.005), sICH per ECASS II definition (OR, 5.527; 95% CI, 1.378–22.167; p=0.016), and sICH per NINDS definition (OR, 3.805; 95% CI, 1.310–11.046; p=0.014). Among the patients with complete data on 3-month mRS score, 226 received IVT plus MT and 262 received IVT alone. No significant difference was reported between IVT plus MT and IVT alone on mRS score 0–1 (72.1% versus 69.1%), mRS score 0–2 (79.6% versus 79%), and death (6.2% versus 6.1%). Conclusions Compared with IVT alone, IVT plus MT was associated with unfavorable shift on 24-h ICH types and higher rate of 24-h PH and sICH in patients with minor stroke and LVO in the anterior circulation. However, no difference was reported between the groups on 3-month functional outcome measures.
- 17 July 2023
- Published by Springer Nature in Neurological Sciences
- Vol. 44 (12) , 4401-4410
IV thrombolysis plus thrombectomy versus IV thrombolysis alone for minor stroke with anterior circulation large vessel occlusion from the IRETAS and Italian SITS-ISTR cohorts
Introduction The aim of this study was to compare the outcomes of patients treated with intravenous thrombolysis (IVT) p=0.013) and higher rate of PH (OR, 4.363; 95% CI, 1.579–12.055; p=0.005), sICH per ECASS II definition (OR, 5.527; 95% CI, 1.378–22.167; p=0.016), and sICH per NINDS definition (OR, 3.805; 95% CI, 1.310–11.046; p=0.014). Among the patients with complete data on 3-month mRS score, 226 received IVT plus MT and 262 received IVT alone. No significant difference was reported between IVT plus MT and IVT alone on mRS score 0–1 (72.1% versus 69.1%), mRS score 0–2 (79.6% versus 79%), and death (6.2% versus 6.1%). Conclusions Compared with IVT alone, IVT plus MT was associated with unfavorable shift on 24-h ICH types and higher rate of 24-h PH and sICH in patients with minor stroke and LVO in the anterior circulation. However, no difference was reported between the groups on 3-month functional outcome measures.
- 1 June 2023
- Published by Bentham Science Publishers Ltd. in Current Medical Imaging
- Vol. 19 (6) , 1
Internuclear Ophthalmoplegia as an Isolated Symptom of Brainstem Wake-up Stroke Responsive to Intravenous Thrombolysis: Evidence from MRI
Background: Internuclear ophthalmoplegia (INO) is a disorder of eye movements caused by a lesion involving the medial longitudinal fasciculus (MLF) within the brainstem, and it is characterized by adduction impairment combined with contralateral dissociated abduction nystagmus. The frequency of acute ischemic stroke (AIS) presenting with INO as a predominant symptom is very low, and many patients suffering from this brainstem AIS are precluded from intravenous thrombolysis (IVT). Objective: To provide for the first time a magnetic resonance imaging (MRI) evidence of response to the IVT in brainstem wake-up stroke presenting with INO as an isolated symptom. Methods: Here, we described a rare case of pons AIS presenting with INO as a unique symptom of awakening. In order to differentiate an ischemic stroke from other stroke mimics, and to determine whether the patient was within the therapeutic window for IVT (wake-up stroke), brain MRI including DWI and FLAIR sequences was acquired. Results: A left paramedian pontine DWI/FLAIR mismatch was detected and the patient was considered eligible for IVT. After IVT, the patient made a full recovery with complete resolution of INO. Follow-up MRI at 1 month demonstrates the absence of ischemic lesions. Conclusion: Our case provides neuroradiological evidence of IVT efficacy in brainstem stroke, and it should prompt clinicians to rapidly perform MRI in wake-up onset INO and to just as quickly administer IVT, since INO is a functionally disabling deficit. Finally, this case demonstrates the value of MRI in diagnostic, prognostic, and therapeutic workup of posterior circulation wake-up stroke.
- 1 June 2023
- Published by Bentham Science Publishers Ltd. in Current Medical Imaging
- Vol. 19 (6) , 1
Internuclear Ophthalmoplegia as an Isolated Symptom of Brainstem Wake-up Stroke Responsive to Intravenous Thrombolysis: Evidence from MRI
Background: Internuclear ophthalmoplegia (INO) is a disorder of eye movements caused by a lesion involving the medial longitudinal fasciculus (MLF) within the brainstem, and it is characterized by adduction impairment combined with contralateral dissociated abduction nystagmus. The frequency of acute ischemic stroke (AIS) presenting with INO as a predominant symptom is very low, and many patients suffering from this brainstem AIS are precluded from intravenous thrombolysis (IVT). Objective: To provide for the first time a magnetic resonance imaging (MRI) evidence of response to the IVT in brainstem wake-up stroke presenting with INO as an isolated symptom. Methods: Here, we described a rare case of pons AIS presenting with INO as a unique symptom of awakening. In order to differentiate an ischemic stroke from other stroke mimics, and to determine whether the patient was within the therapeutic window for IVT (wake-up stroke), brain MRI including DWI and FLAIR sequences was acquired. Results: A left paramedian pontine DWI/FLAIR mismatch was detected and the patient was considered eligible for IVT. After IVT, the patient made a full recovery with complete resolution of INO. Follow-up MRI at 1 month demonstrates the absence of ischemic lesions. Conclusion: Our case provides neuroradiological evidence of IVT efficacy in brainstem stroke, and it should prompt clinicians to rapidly perform MRI in wake-up onset INO and to just as quickly administer IVT, since INO is a functionally disabling deficit. Finally, this case demonstrates the value of MRI in diagnostic, prognostic, and therapeutic workup of posterior circulation wake-up stroke.